Wedbush Has Optimistic Outlook of PTGX Q3 Earnings

Key Points

• Wedbush raised its Q3 2025 earnings estimates for Protagonist Therapeutics, now projecting a loss of ($0.57) per share, an improvement from the previous forecast of ($0.62).
• The company reported a revenue of $5.55 million for its most recent quarter, missing the analysts' expectations of $8.32 million, while also posting a loss of ($0.55) earnings per share.
• Protagonist Therapeutics has received various ratings, with a consensus rating of "Moderate Buy" and an average target price of $67.20, highlighting positive sentiment from multiple brokerages.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities research analysts at Wedbush boosted their Q3 2025 earnings per share (EPS) estimates for Protagonist Therapeutics in a research report issued to clients and investors on Thursday, August 7th. Wedbush analyst Y. Zhong now forecasts that the company will post earnings per share of ($0.57) for the quarter, up from their previous forecast of ($0.62). The consensus estimate for Protagonist Therapeutics' current full-year earnings is $2.43 per share. Wedbush also issued estimates for Protagonist Therapeutics' Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($1.91) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($0.35) EPS.

Other research analysts have also issued reports about the stock. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, June 3rd. JMP Securities boosted their price objective on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a "market outperform" rating in a research report on Thursday, August 7th. Citigroup restated an "outperform" rating on shares of Protagonist Therapeutics in a research report on Thursday, August 7th. Finally, Wall Street Zen raised shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, June 8th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $67.20.

Protagonist Therapeutics Price Performance

NASDAQ:PTGX traded up $0.78 during mid-day trading on Monday, reaching $54.53. The stock had a trading volume of 541,716 shares, compared to its average volume of 945,091. The company has a market capitalization of $3.39 billion, a price-to-earnings ratio of 77.90 and a beta of 2.33. The stock's 50 day simple moving average is $53.95 and its two-hundred day simple moving average is $47.59. Protagonist Therapeutics has a 1-year low of $33.31 and a 1-year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.02). The company had revenue of $5.55 million for the quarter, compared to analyst estimates of $8.32 million. Protagonist Therapeutics had a return on equity of 8.12% and a net margin of 24.88%.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 22,065 shares of the business's stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $55.05, for a total transaction of $1,214,678.25. Following the transaction, the chief executive officer owned 548,538 shares in the company, valued at approximately $30,197,016.90. The trade was a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $57.03, for a total value of $570,300.00. Following the completion of the sale, the insider owned 83,892 shares in the company, valued at approximately $4,784,360.76. This represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,859 shares of company stock worth $4,020,877 in the last quarter. Insiders own 4.90% of the company's stock.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jefferies Financial Group Inc. grew its holdings in shares of Protagonist Therapeutics by 30.4% during the 2nd quarter. Jefferies Financial Group Inc. now owns 824,019 shares of the company's stock worth $45,544,000 after purchasing an additional 192,126 shares in the last quarter. Prudential Financial Inc. raised its position in shares of Protagonist Therapeutics by 32.6% in the 2nd quarter. Prudential Financial Inc. now owns 77,408 shares of the company's stock worth $4,278,000 after acquiring an additional 19,050 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Protagonist Therapeutics by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company's stock valued at $44,990,000 after acquiring an additional 128,171 shares during the period. Segall Bryant & Hamill LLC bought a new position in shares of Protagonist Therapeutics during the 2nd quarter worth about $6,641,000. Finally, Rhumbline Advisers raised its position in shares of Protagonist Therapeutics by 6.8% during the second quarter. Rhumbline Advisers now owns 173,028 shares of the company's stock worth $9,563,000 after purchasing an additional 10,963 shares during the period. 98.63% of the stock is owned by institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.